MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL)
Molica S, Giannarelli D, Gentile M, et al.
Key Points:
Investigators assessed prognostic significance of new prognostic index proposed by MD Anderson Cancer Center (MDACC)
4 groups identified- HC-MBL with MDACC score < 25; HC-MBL with MDACC score >=25; Rai stage 0 with MDACC score < 25; Rai stage 0 with MDACC score >=25
5-year probability of remaining free from therapy: 97% for HC-MBL and MDACC score <25; 20% for Rai stage 0 and score >=25; 68% for the other 2 groups
Implications:
- MDACC score adds information to the distinction between HC-MLB and Rai stage 0 leading to the identification of three significantly different patterns of TTFT (Time to First Treatment)
View the original abstract on the ASH website.
